%A Wagner,Michael %A Maki,Robert %D 2013 %J Frontiers in Oncology %C %F %G English %K insulin-like growth factor pathway,pediatric cancer,Sarcoma,resistance mechanisms,IGF-1R %Q %R 10.3389/fonc.2013.00009 %W %L %M %P %7 %8 2013-February-04 %9 Mini Review %+ Dr Robert Maki,Mount Sinai School of Medicine,Departments of Medicine, Pediatrics, and Orthopedics,1 Gustave L. Levy Place, Box 1208,New York,10029-6574,NY,United States,bobmakimd@gmail.com %# %! IGF-1R inhibitors in pediatric cancer %* %< %T Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer %U https://www.frontiersin.org/articles/10.3389/fonc.2013.00009 %V 3 %0 JOURNAL ARTICLE %@ 2234-943X %X Data from over 20 years ago demonstrated potential use for insulin-like growth factor (IGF) signaling modulators, specifically with IGF-1R antagonists, in a variety of pediatric and adolescent cancers, particularly in sarcomas. However, in spite of promising preclinical data, IGF-1R inhibitors have not had the success as single agents that was originally hoped for in clinical trials. Several potential mechanisms exist by which tumors are resistant to IGF-1R inhibitors. Notably, these resistance mechanisms are currently best understood in Ewing sarcoma and alveolar rhabdomyosarcoma. Various treatment schema have been proposed as a potential way to overcome this resistance. The use of IGF-1R inhibitors, mechanisms of resistance, and current ongoing clinical studies using IGF-1R inhibitors in pediatric cancers are reviewed here.